Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ambulance sepsis blitz: early treatment cuts deaths?

NCT ID NCT02473263

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 2 times

Summary

This study tested whether giving strong, early treatment to people with severe sepsis or septic shock right in the ambulance could lower the number of deaths. The treatment included early antibiotics and fluids to support blood pressure. The study involved 398 adults and measured how many patients died, as well as their hospital stay and need for life support.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

398 people

The number who actually took part.

Started

May 2016

Finished

Feb 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All patients fulfilling the following criteria: * Age ≥ 18 years * Patient with suspected severe infection defined by the existence of a suspected infection AND * Hypotension before vascular fluid loading AND/OR * Lactataemia greater than 4 mmol/l AND/OR * Glasgow scale lower than 13 AND/OR * Mottling score greater than 2 * Patient with a septic shock Exclusion Criteria: * Age \<18 years or Unable * Pregnant * Severe concomitant pathology requiring urgent care(i.e.epilepsy) * Status "not to be reanimated" life expectancy less than 6 months with no indication of reanimation support ( prior decision on care limitation). * Fulminans purpura * True allergy to beta-lactam defined by an angioedema or by an anaphylactic shock during a prior exposure to beta-lactam. * Patient who have already received hemodynamic optimization or antibiotic treatment before the MICU's (Mobile Intensive Care Unit) care.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe septic syndrome (severe sepsis and septic shock) diagnosed and treated by mobile intensive care unit are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease Sepsis Toxemia toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe septic syndrome (severe sepsis and septic shock) diagnosed and treated by mobile intensive care unit

Contacts and locations

Locations

  • Anesthesiology, Intensive Care Unit and emergency department - Necker Hospital

    Paris, 75015, France